The c-myb proto-oncogene encodes a nuclear protein involved in the regulation of cell proliferation, differentiation, and development. Myb protein contains a DNA binding and a transactivating domain thought to mediate its biologic properties. The DNA binding domain consists of three repeats (RI, R2, and R3). each containing a highly conserved motif of tryptophan residues. A c-myb mutant (DM-myb) lacking the last 46 amino acids of R1 and 23 amino terminal residues of R2, a region homologous to the ADA-2 yeast transcriptional adaptor, lost DNA binding ability, but remained able to transactivate the human heat-shock promoter. Transfection of murine 32D and murine erythroleuke-HE PROTO-ONCOGENE c-myb encodes a nuclear protein whose function is required for cell proliferation and differentiati~n"~ as well as during development.s c-myb is predominantly expressed in hematopoietic cells; in contrast, B-myb, another member of the Myb family, is ubiquitously expressed and may exert myb-like functions in other cell types.' It has been demonstrated that c-myb is a transcriptional activator that contains a DNA binding domain as well Myb-responsive promoter.15 Nevertheless, this truncated Myb was capable of transforming avian hematopoietic cells." This effect might reflect transactivation of a subset of Myb-responsive genes containing low-affinity Myb binding sites in their regulatory regions; however, it is also consistent with previous studies reporting that c-myb is endowed with a DNA binding-independent transactivation activity."." We were particularly intrigued by the observation that some of the naturally occurring mutations in v-myb oncoproteins or mutations artificially introduced in the DNA binding region of c-myb dramatically altered Myb transactivation activity or the phenotype of myb-transformed cells.12~'x Such activating mutations are located predominantly within the tryptophan repeats of Myb, which includes a region homologous to the ADA-2 yeast transcriptional adaptor," which may bridge certain acidic enhancer proteins to the basal transcription machinery located at the transcriptional start site, thereby regulating the activity of transcription factors.
HE PROTO-ONCOGENE c-myb encodes a nuclear protein whose function is required for cell proliferation and differentiati~n"~ as well as during development.s c-myb is predominantly expressed in hematopoietic cells; in contrast, B-myb, another member of the Myb family, is ubiquitously expressed and may exert myb-like functions in other cell types.' It has been demonstrated that c-myb is a transcriptional activator that contains a DNA binding domain as well as transcriptional and repressor domain^.^ The region involved in DNA binding consists of three imperfect tryptophan repeats located near the amino-terminus, namely RI, R2, and R3.8 Repeats 2 and 3 are required for DNA binding activity: and the amino acid residues critical for the interaction of Myb with the DNA helix have been identified.'" The viral forms of the Myb protein have a 70-amino acid deletion encompassing the RI repeat at the amino-terminus of the protein; such truncation does not affect DNA binding as compared with the cellular counterpart, and results in increased transcriptional activation and cellular transformation.''-" However, more recent studies suggest that the RI element might be required for stabilization of the binding of Myb to its binding sites14 or for transcriptional activator function since removal of R1 actually decreased Myb transactivation activity and DNA binding affinity to the mim-l Myb-responsive promoter.15 Nevertheless, this truncated Myb was capable of transforming avian hematopoietic cells." This effect might reflect transactivation of a subset of Myb-responsive genes containing low-affinity Myb binding sites in their regulatory regions; however, it is also consistent with previous studies reporting that c-myb is endowed with a DNA binding-independent transactivation activity."." We were particularly intrigued by the observation that some of the naturally occurring mutations in v-myb oncoproteins or mutations artificially introduced in the DNA binding region of c-myb dramatically altered Myb transactivation activity or the phenotype of myb-transformed cells.12~'x Such activating mutations are located predominantly within the tryptophan repeats of Myb, which includes a region homologous to the ADA-2 yeast transcriptional adaptor," which may bridge certain acidic enhancer proteins to the basal transcription machinery located at the transcriptional start site, thereby regulating the activity of transcription factors.
In this report, we show that a constitutively expressed deletion mutant lacking the last 46 amino acids of R1 and the first 23 amino acids of R2 (ADA-2 homology region), inhibits murine myeloid and erythroid cell differentiation; however, a c-myb mutant lacking only the initial 23 amino acids of R2 lost the DNA binding and transactivation activity, but had no effect on DMSO-induced differentiation of MEL cells. These findings suggest that deletion of R I activates a DNA binding independent mechanism of Myb function that interferes with erythro-myeloid differentiation.
MATERIALS AND METHODS

Plasmid construction.
Cloning of the DRIpFLAG construct was performed as follows: the pFLAG-myb vector2" was linearized with RsrII, then Klenow blunted and digested with NCO I. The pFLAG-myb deleted of the NCO I-RsrII fragment was ligated to a Ncu I-Sma I c-myb segment obtained by digestion of the pFLAGmyb construct. The c-my6 expression vector plasmid pMbmI has been described.' The pMbmI-DR1 plasmid was obtained after ligation of the NCO I-EcoRI segment obtained by PCR amplification of the DRl-pFLAG, and the pMbmI plasmid deleted of the corresponding NCO I-EcoRI fragment. The GST-myb plasmids pGEX-c-myb and pGEX-DRI were obtained by subcloning a blunted NCO I-Psf I fragment from p M b d or pMbmI-DR1 into a blunted pGEX-2TKE2F-1 vector in which the E2F-1 cDNA was removed by cutting with BamHI and EcoRI. The NCO I-PSI I fragment corresponds to nucleotides I 12-710 in the wild-type c-my6 cDNA and spans the entire DNA binding domain. The vector LXSN" was linearized with Xho 1 and the c-my6 or the DRI complete cDNA segments were inserted at the Xho I site to obtain plasmids LXSN-myb and plasmid LXSNDRI. The D-ADA2 c-myb mutant was first obtained by digesting the pGEX-c-myb constmct (obtained by subcloning a blunted NCO I-xh I fragment containing the entire coding region plus the 3' untranslated region of c-myb into the pGEX vector) with the restriction enzymes Sac I and RsrII, blunting with T4 polymerase (Boehringer Mannheim, Mannheim, Germany), and religating the deleted myb construct with T4 ligase. Correct orientation and frame of the construct were determined by sequence analysis. Plasmid pMbm-D-ADA-2 (c-myb cDNA deletion mutant under the control of the SV40 early promoter) was obtained by digestion of the c-myb expression vector pMbm1 with Sma I, which resulted in the removal of a Sma I-Sma I fragment encompassing the ADA-2 homology region. The Sma I-Sma I fragment of the wild-type c-myb cDNA was replaced with that derived from the pGEX-D-ADA-2 construct. Orientation and frame of the construct were confirmed by sequence analysis.
Cell lines and transfections. The 32D cell line has been described." Cells were electroporated with the different retroviral constructs containing the ne0 resistance gene, and 48 hours later, transferred to selective medium containing 1 m g / d G418. After 13 days, resistant clones emerged and the resulting cell lines were maintained in medium containing 500 pg/mL G418. Murine erythroleukemia (MEL) cells were routinely passaged in Dulbecco's minimal Essential medium (DMEM) supplemented with 10% fetal calf serum (FCS). Plasmids pMbml, pMbmI DRlmyb, and pMbm-D-ADA-2 were transfected into MEL cells along with a plasmid containing the G41 8 resistance gene (1 0 1 ratio) using lipofectin reagents (GIBCO, Grand Island, NY). After 14 days of selection in 800 pg/mL G418 containing medium, cell lines were established. Differentiation of MEL cells was analyzed by plating 5 X IO4 celIs/mL in medium containing 1.5% DMSO and scoring hemoglobin-producing cells by benzidine staining S days later.
Chloramphenicol-acetyl-transferase {CAT) assays. CAT activity was assayed as described'" in TK-tsl3 hamster fibroblastsz3 transfected by the calcium-phosphate precipitation method?4 Transfection efficiency was normalized using as internal control 1 pg of a plasmid containing the bacterial P-galactosidase gene driven by the DNA polymerase-a promoter.
Production of GST fusion protein. Get-retardation ussay, Different amounts of GST-myb fusion proteins were mixed with a 32P-labeled double-stranded oligonucleotide probe including the Myb binding site (box A of the mim-l promoter) and gel-retardation assays were performed as described?' PCR reactions. To assess genomic integration of c-myb constructs in transfected MEL cells, PCR reactions were performed using 1 0 0 ng of total genomic DNA (or 100 pg of plasmid DNA as control) and 300 ng of each primer in a total volume of 50 pL. After 35 cycles (45 seconds at 94°C 45 seconds at 52"C, 30 seconds at 72"C), 10 pL from each sample were analyzed by agarose electrophoresis and ethidium bromide staining. Primers correspond to nucleotides 20.5-228 and reverse complementary of nucleotides 574-570 of the human c-myb cDNA. To assess expression of human cmyb mFWA, 0.5 pg of total RNA from each cell line was reversetranscribed and PCR-amplified (RT-PCR) using human-specific primers corresponding to nucleotides 2255-2278 and reverse complementary of nucleotides 2460-2483 of the human c-myb cDNA.
A 300 ng sample of each primer was used for a SO pL PCR reaction.
After 3.5 cycles (45 seconds at 94°C. 45 seconds at 52°C 30 seconds at 72"C), 10 pL from each sample was subjected to electrophoresis, transferred onto a nylod filter, and hybridized with a 32P-labeled synthetic oligonucleotide probe specific for the 229-bp amplified fragment. Northern blot. To induce erythroid differentiation, cells were plated at S X IO* ceIls/mL in DMEM medium containing 10% fetal bovine serum and 1.5% DMSO. After S days, cells were collected and total RNA was prepared as de~cribed.~' Seven micrograms from each sample was fractionated in 1.2% agarose denaturing gel and transferred onto nitrocellulose. Probes for hybridization were a "Plabeled 400-bp Not I-EcuRI fragment from human @-globin cDNA and a 32P-labeled 2.1 -Kb X h o I fragment containing the full-length P-actin cDNA. The same filter was hybridized sequentially with both probes at 42°C in the presence of 50% formamide and washed at high stringency ( 0 . 2~ SSC and 65°C). Densitometry of the corresponding autoradiogram was performed in an UltroScan XL apparatus (Pharmacia Biotech, Sweden).
Western blot analysis. Myb protein was detected in lysates of transfected cells using a commercial anti-Myb monoclonal antibody as described.26 transfected lines27 was used to assess the transactivating abil-" F F F n n n * * * ity of DRI-myb. In transiently transfected TK-tsI3 cells, the wild-type Myb transactivated the c-myb promoter 8-to 10-fold ( Fig 3A, lane 2) . whereas no transactivation was observed using DRI-myb cDNA (Fig 3A, lane 3) . Transfected cells expressed similar amounts of wild-type or deleted Myb protein (Fig 3B) , which excludes the possibility that the lack of a transactivating effect reflected degradation or instability of the deleted protein. We also used transactivation assays to test the effects of the c-myb constructs on the Myb-responsive CD34 promoter.2h In contrast to the full-length c-myb cDNA, the DRI-myb cDNA construct was unable to transactivate this promoter (not shown). Similar studies were conducted on the heat shock promoter (HSP)-CAT construct, previously shown to be transactivated by c-myh in a DNA binding-independent manneri7; in contrast with the effects observed using the c-myb-CAT or the CD34-CAT plasmids, DR-1 -myb was able to transactivate the HSP-CAT construct (Fig 4) . In three different experiments, wild-type and DR-I tein (DRI-myb) deleted of R1 (the last 46 amino acids) and of 23 residues of the aminoterminal portion of R2, which corresponds to the ADA-2-like element (Fig l) , a Sma IRsrll segment was removed from the GST-Myb construct. Bacterially produced GST-DR1 and GST-myb proteins were then assayed in gel-shift experiments for the ability to interact with the canonical Myb binding site identified in the promoter of the Myb-responsive gene mim-l." The GSTmyb protein bound efficiently to a double-stranded oligomer containing the mim-I Myb binding site, while no interaction was detected using the GST-DR1-myb protein (Fig 2) . The same results were obtained using Myb proteins produced with the pFLAG system and reacted with Myb binding sites included in the CD34 or the c-myb promoter (not shown).
RESULTS
Deletion
Transactivation activity of the DRI-myb construct is independent of DNA binding. To determine whether the loss of DNA binding activity of the DRI-myb construct correlated with a similar inability to transactivate Myb-responsive promoters, we investigated the effect of the wild-type and the DNA binding-deficient Myb constructs on the promoter activity of c-myb and HSP genes. Myb induced a fivefold and a fourfold transactivation of the HSP-CAT construct, respectively.
DRI-m-yb inhibits granulocyte colony-stimulating factor (G-CSF)-induced granulocyte differentiation of 320 cells.
To assess whether DR 1 -myb expression might have biologic consequences, we investigated the role of this mutant in two murine cell lines 32D and MEL, whose hematopoietic differentiation is perturbed by ectopic v-myb and c-myb expression, re~pectively.'.~ In 32D cells, expression levels of endogenous c-myb remain high throughout the G-CSF-induced differentiation process except in the latest days of culture, when the cells assume a fully differentiated phenotype." Such kinetics of expression suggests that c-myb, per se, might not be sufficient to interfere with 32D cell differentiation, and instead is able to do so by activating mutation(s) and/or by deletions present in its oncogenic counterpart. Thus, because deletion of R I and of the aminoterminal part of R2 abolished the DNA binding capacity of Myb, but did not affect DNA binding-independent transactivation, we assessed whether our DRI-myb mutant interferes with 32D cell differentiation. We subcloned c-myb and DRI-myb cDNAs downstream of the Moloney leukemia virus (MLV)-LTR into the LXSN retroviral vector, which also contains the neomicin resistance gene. Following electroporation and G41 8 selection, two independent mixed populations of each different construct were analyzed for expression of the myb transgenes (Fig 5A) and the capacity to undergo terminal differentiation. Mixed cell populations were preferred to single cell clones to avoid artifacts due to clonal selection. After IO or 14 days in medium containing G-CSF, cells were stained and subjected to morphologic analysis. Control ( Fig  6A) and myb-transfected (Fig 6, B and C) cells were able to undergo terminal differentiation; however, a higher percentage of intermediate forms was noted in the myb transfectants, especially in the DRI cell line (Fig 6C) . In fact, promyelocytic-metamyelocytic stage cells accounted for approximately 28% of the DRI cell line, as compared with 14% of the c-myb cell line and 6% of the cell line transfected with the insertless vector control (Table l) . Western blot analysis of LXSN-myb and LXSN-DRI cell lines showed that Myb protein expression was still elevated after I O days of culture in G-CSF, while endogenous myb expression was turned off in the control cell line (Fig 5B) . indicating that LTR-driven expression of exogenous Myb proteins was not affected by G-CSF.
DRI-mvb inhibits DMSO-induced erythroid differentiation of MEL cells. The MEL cell line provides a model of early erythroid precursors that can be induced to terminally
-exog.
-end. we used pMbm1 plasmid carrying the wild-type c-myb cDNA. After selection in C41 8, mixed populations expressing exogenous human c-myb (MEL/c-myb) or DRI-myb (MEUDRI) were established. We also selected four individual clones expressing DRI-myb (MEL/D#I. MEL/D#2, MEL/D#3, and MEL/ D#4). Plasmid genomic integration (Fig 7A) and exogenous mRNA expression (Fig 7B) were confirmed by PCR.
. . For differentiation assay. cells were plated at S X 10' cells/mL in the presence of 1.5% DMSO. The number of differentiated cells was scored 5 days after DMSO treatment by counting the proportion of cells stained with benzidine. As shown in Fig 8A, the proportion of differentiated cells was lower in the cell population expressing exogenous wildtype c-myb compared with the two control cell lines (MEL and MELheo), in agreement with previous observations.3 The inhibitory effect on MEL differentiation was also evident in mixed and clonal cell populations expressing DRImyb. This result was confirmed by Northern blot analysis of @-globin mRNA levels in MEL cells, and MEL/neo, MEW c-myb, and MELlDRI cell lines, after 5 days of treatment with DMSO (Fig 8B) . Densitometric analysis of the autoradiograms revealed 60% and 80% inhibition of @-globin mRNA induction in MEL/c-myb and MEUDRI cells, respectively.
ADA-2-myb mutant lacks DNA binding and transcrctiwting activity and does not inhibit DMSO-induced erythroid differentiation of MEL cells. To determine whether the deletion of RI or of the ADA-2 homology region in R2 was important for the phenotype of DR-I transfected cells, we prepared a new cDNA mutant with an internal deletion of the ADA-2 homology region. This cDNA mutant was first prepared in the GST vector to generate bacterially expressed protein and then placed under the control of the SV40 early promoter for transfection studies in MEL cells. Gel-shift experiments with a double-stranded oligomer including the mim-l Myb binding site showed that, like DRI-myb, D-ADA2-myb was also unable to interact with this site (Fig  9A) . Like DRI-myb, the D-ADA2-myb mutant was also unable to transactivate either the c-myb (Fig 9B) or the CD34 promoter (not shown). In contrast, the wild-type c-myb construct did transactivate 6-to 7-fold the c-myb promoter ( Fig  9B) . Similar levels of wild-type and mutant proteins were detected in the transfected cells (Fig 9C) , confirming the specificity of the effects. After transfection in MEL cells, two mixed cell populations found to express the D-ADA-2 myb construct (Fig 10A) were exposed to DMSO and assessed for their ability to undergo erythroid differentiation. The fraction of differentiated cells in the D-ADA-2 myb transfectants was essentially identical to that of parental and vector-transfected MEL cells ( Fig 10B) ; in contrast DMSOinduced differentiation was inhibited in MEL cells -were air-dried and stained by Giemsa-Wright.
transfected with wild-type c-myh or DRI-Myb (Fig IOB) .
For -P -actin that removal of the R 1 segment of the DNA binding domain diminishes c-my/? ability to transactivate the differentiationspecific promoter mim-I , perhaps as consequence of a reduced affinity of the truncated protein to the Myb binding site; nevertheless, the truncation resulted in oncogenic activation of c-myb." The RI element is evolutionary conserved. but is lost in the viral forms of Myb. The proximal portion of R2, which is also a highly conserved element, is homologous to the yeast transcriptional adaptor ADA-2 and thus may be involved in protein-protein interactions. Internal deletion of a c-myb segment that includes the last 46 amino acids of RI and the initial 23 amino acids of R2 results in loss of DNA binding and in inability to transactivate genes via a DNA binding mechanism; however, the DNA bindingindependent transactivation ability of c-mnyh was maintained. Interestingly, the DRI myb mutant inhibits erythro-myeloid differentiation, a function previously associated with overexpressed wild-type c-myh or v-rnyh."' These findings are in apparent contrast with those of Cuddahy et al"' who reported that the DNA binding activity is required to block terminal differentiation of MEL cells. However, R2 was entirely deleted in one of their two DNA binding-deficient mutants, whereas our DRI mutant lacks only the initial 23 amino acids of R2. The other DNA binding-deficient mutant had a tryptophan to glycine mutation that abolishes DNA binding, but leaves unaffected c-myb residues in RI and R2 that may be involved in protein-protein interactions (see below). To determine whether the critical region of the DRI mutant was RI or the aminoterminal region of R2, a second mutant, D-ADA-2 lacking only the initial 23 amino acids of R2 was assayed for DNA binding and transactivating activity and for the ability to inhibit DMSO-induced differentiation of MEL cells. The ADA-2 deletion mutant was unable to interact with the mim-l Myb binding site, and to transactivate promoter responsive to c-myb in a DNA binding-dependent manner. Moreover, it was unable to inhibit DMSO-induced erythroid differentiation of MEL cells, supporting the critical role of R1 for the inhibitory effects on MEL differentiation. Interestingly, the ADA-2 deletion removes not only a residue (Lys-92) involved in DNA binding,30 but also two residues (Ile-91 and Leu-106) postulated to be involved in proteinprotein intera~tion.~' The biologic effects we observed might rest in the ability of DR1 to transactivate a subset of Mybresponsive promoters in a DNA binding-independent manner or, as suggested by Dini and Lipsick," in the transactivation of a subset of Myb responsive genes that may contain low affinity Myb binding sites in their regulatory regions. An alternative explanation is that R1 regulates Myb activity by interacting with specific proteins or by competing with R2 and/or R3 for interaction with the same proteins subset. In this regard, Leu-l06 and Val-l 17, two residues of R2 postulated to be involved in protein-protein interaction:' are also present in R1. Depending on the binding of factors to the DNA-binding domain, Myb might transactivate certain promoters differentially, which would explain the marked difference of Myb transcriptional activity in different cell types."
In 32D cells, v-myb can completely block differentiation and render these cells able to proliferate in the presence of G-CSP; in our transfectants we did not observe the same striking effects, possibly reflecting the lower activity of the human c-myb. Both c-myb and the DNA binding deficient mutants contain the leucine zipper region, which is absent in v-myb and has been shown to mediate Myb homodimerization and negative regulation of Myb activity."
The present data establish that R1 has a critical role as modulator of Myb activity. RI can interact with regulatory proteins and affect Myb activity; removal of R1 can also increase the potential for protein-protein interaction at the R2 and R3 sites not involved in DNA binding. This is consistent with previous observations that the transforming potential of v-myb and the phenotype of cells infected by viruses carrying the oncogene18 is influenced by mutations clustered within the first portion of R2, and encompassing the ADA-2-like region. Those investigators speculated that putative cellular factors might interact with that region of v-myb, given that the structural characteristics of the tryptophan motif make it compatible with potential protein-protein interactions. In addition, a recent study suggests that putative protein-protein interactions at the level of the second and third myb repeats can determine its transformation and transactivation ability.33 Our preliminary findings of a 30-kD cellular factor that interacts with the myb tryptophan repeat located within R2, supports these studies. Further understanding of c-rnyb function and its involvement in leukemogenesis awaits identification of factors involved in the control of Myb activity and its transforming potential,
